Loading clinical trials...
Loading clinical trials...
A Randomized, Parallel-group, Placebo Control, Non-inferiority Trial to Investigate the Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
Growing evidence of Tranexamic Acid (TXA) being used to reduce blood loss and blood transfusions in various guidelines. However, the adverse effects of TXA especially seizure has always been a problem of concern, especially in neurosurgery. Therefore, this study aims to provide a scientific evidence for the safety of TXA in supratentorial meningiomas resection patients.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Start Date
October 30, 2020
Primary Completion Date
January 11, 2024
Completion Date
July 11, 2024
Last Updated
March 4, 2025
228
ACTUAL participants
Tranexamic acid
DRUG
0.9% saline
DRUG
Lead Sponsor
Beijing Tiantan Hospital
NCT05077904
NCT05940493
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05667142